This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rabascio, C. Articles by Bertolini, F. Search for Related Content PubMed PubMed Citation Articles by Rabascio, C. Articles by Bertolini, F.

Assessing Tumor Angiogenesis

Increased Circulating VE-Cadherin RNA in Patients with Cancer Indicates Viability of Circulating Endothelial Cells

Divisions of ¹ Hematology-Oncology and ² Medical Oncology, Department of Medicine and ³ Divisions of Thoracic Surgery and ⁴ Pathology-Laboratory Medicine, European Institute of Oncology, Milan, and ⁵ Medical Hepatology Unit, Maggiore Hospital and University of Milan, Italy

No markers are currently available to indicate the angiogenic profile of a specific malignant disease nor to predict response to antiangiogenic therapies. Nevertheless, many different antiangiogenic drugs are presently being tested in many clinical trials, with an obvious scarcity of useful endpoints for treatment outcome beside survival. By means of a quantitative reverse transcription-PCR approach, we measured VE-cadherin (VE-C), Tie-2, vascular endothelial growth factor receptor 2 and CD133 RNA in the blood of 14 healthy controls, 3 pregnant women, and 84 newly diagnosed (or relapsed) cancer patients. Circulating VE-C RNA was increased in pregnant women and cancer patients (P = 0.0002). VE-C RNA was particularly increased in patients affected by hematological malignancies and decreased to normal values in patients achieving complete remission. Conversely, circulating RNA levels of other endothelial or progenitor cell-specific markers Tie-2, vascular endothelial growth factor receptor 2, and CD133 were not significantly increased in either pregnant women or cancer patients. Comparison of various surrogate angiogenesis markers indicated a switch toward increased plasma vascular endothelial growth factor (VEGF) levels, viable circulating endothelial cells, and circulating VE-C RNA levels in patients affected by hematological malignancies. Taken together, our data indicate that the quantitative evaluation of circulating VE-C RNA is a specific and highly promising tool with which to investigate the angiogenic phenotype of cancer patients.

This article has been cited by other articles:

				A. Fontana, L. Galli, A. Fioravanti, P. Orlandi, C. Galli, L. Landi, S. Bursi, G. Allegrini, E. Fontana, R. Di Marsico, et al. Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer Clin. Cancer Res., August 1, 2009; 15(15): 4954 - 4962. [Abstract] [Full Text] [PDF]

				P. Mancuso, P. Antoniotti, J. Quarna, A. Calleri, C. Rabascio, C. Tacchetti, P. Braidotti, H.-K. Wu, A. J. Zurita, L. Saronni, et al. Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses Clin. Cancer Res., January 1, 2009; 15(1): 267 - 273. [Abstract] [Full Text] [PDF]

				J. L. G. Bender, P. C. Adamson, J. M. Reid, L. Xu, S. Baruchel, Y. Shaked, R. S. Kerbel, E. M. Cooney-Qualter, D. Stempak, H. X. Chen, et al. Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study J. Clin. Oncol., January 20, 2008; 26(3): 399 - 405. [Abstract] [Full Text] [PDF]

				R. S. Bhatt, P. Seth, and V. P. Sukhatme Biomarkers for Monitoring Antiangiogenic Therapy Clin. Cancer Res., January 15, 2007; 13(2): 777s - 780s. [Abstract] [Full Text] [PDF]

				N. Mehra, M. Penning, J. Maas, L. V. Beerepoot, N. van Daal, C. H. van Gils, R. H. Giles, and E. E. Voest Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases. Clin. Cancer Res., August 15, 2006; 12(16): 4859 - 4866. [Abstract] [Full Text] [PDF]

				B. Dome, J. Timar, J. Dobos, L. Meszaros, E. Raso, S. Paku, I. Kenessey, G. Ostoros, M. Magyar, A. Ladanyi, et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res., July 15, 2006; 66(14): 7341 - 7347. [Abstract] [Full Text] [PDF]

				P. Mancuso, M. Colleoni, A. Calleri, L. Orlando, P. Maisonneuve, G. Pruneri, A. Agliano, A. Goldhirsch, Y. Shaked, R. S. Kerbel, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy Blood, July 15, 2006; 108(2): 452 - 459. [Abstract] [Full Text] [PDF]

				D. A. Smirnov, B. W. Foulk, G. V. Doyle, M. C. Connelly, L. W.M.M. Terstappen, and S. M. O'Hara Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Res., March 15, 2006; 66(6): 2918 - 2922. [Abstract] [Full Text] [PDF]

				R. G. Bagley, W. Weber, C. Rouleau, and B. A. Teicher Pericytes and Endothelial Precursor Cells: Cellular Interactions and Contributions to Malignancy Cancer Res., November 1, 2005; 65(21): 9741 - 9750. [Abstract] [Full Text] [PDF]